Neo Ivy Capital Management Arrowhead Pharmaceuticals, Inc. Transaction History

Neo Ivy Capital Management

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 23, 2024	BUY	$21.2 - $31.03 $28,344 - $41,487	1,337 New	1,337 $41,000
Q4 2022 Mar 24, 2023	BUY	$28.0 - $40.56 $806,960 - $1.17 Million	28,820 Added 3540.54%	29,634 $1.2 Million
Q3 2022 Nov 15, 2022	BUY	$29.63 - $48.31 $24,118 - $39,324	814 New	814 $27,000
Q1 2022 May 16, 2022	SELL	$39.62 - $69.97 $7,805 - $13,784	-197 Closed	0 $0
Q4 2021 Feb 15, 2022	BUY	$58.09 - $82.51 $11,443 - $16,254	197 New	197 $13,000
Q3 2021 Nov 16, 2021	SELL	$58.38 - $84.96 $4,203 - $6,117	-72 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$62.15 - $90.32 $4,474 - $6,503	72 New	72 $6,000
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $16,344 - $31,843	-373 Closed	0 $0
Q3 2020 Nov 17, 2020	BUY	$33.21 - $51.27 $8,136 - $12,561	245 Added 191.41%	373 $16,000
Q2 2020 Aug 17, 2020	BUY	$26.12 - $43.27 $3,343 - $5,538	128 New	128 $5,000
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $4,482 - $13,760	-218 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$28.14 - $73.01 $6,134 - $15,916	218 New	218 $14,000
Q3 2019 Nov 21, 2019	SELL	$26.26 - $34.86 $3,361 - $4,462	-128 Closed	0 $0
Q2 2019 Aug 15, 2019	BUY	$17.43 - $28.82 $2,231 - $3,688	128 New	128 $3,000

295

91.1M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.96B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.